P. Lorenzini

发表

Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART.

P. Narciso, G. Ippolito, A. Corpolongo, 2005, AIDS research and human retroviruses.

Antiretroviral treatment‐based cost saving interventions may offset expenses for new patients and earlier treatment start

G. Ippolito, A. Mammone, P. Lorenzini, 2014, HIV medicine.

Triglycerides / HDL Ratio And Its Impact On Risk Of Diabetes Mellitus Development During 1 Antiretroviral Therapy 2 Short running title : Triglycerides / HDL Ratio and Diabetes ' risk 3

A. Antinori, P. Lorenzini, A. Monforte, 2017 .

Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome

G. D'offizi, C. Agrati, G. Ippolito, 2020, Cell Death & Disease.

HIV Type 1 replication in cerebrospinal fluid of patients with AIDS-related non-Hodgkin's lymphoma receiving chemotherapy and antiretroviral therapy.

M. Capobianchi, A. Antinori, P. Lorenzini, 2003, AIDS research and human retroviruses.

Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study

A. d’Arminio Monforte, P. Lorenzini, G. Guaraldi, 2019, European Journal of Clinical Microbiology & Infectious Diseases.

Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus

A. d’Arminio Monforte, A. Antinori, P. Lorenzini, 2015, PloS one.

Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, The Journal of antimicrobial chemotherapy.

Myeloid Derived Suppressor Cells Expansion Persists After Early ART and May Affect CD4 T Cell Recovery

C. Agrati, E. Cimini, A. Sacchi, 2019, Front. Immunol..

CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.

A. d’Arminio Monforte, E. Nicastri, A. Antinori, 2015, The lancet. HIV.

An anal cancer screening program for MSM in Italy: Prevalence of multiple HPV types and vaccine-targeted infections.

M. Capobianchi, P. Lorenzini, A. Ammassari, 2015, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2013, The Journal of antimicrobial chemotherapy.

Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients.

A. Antinori, P. Cinque, V. Tozzi, 2006, AIDS research and human retroviruses.

Spontaneous ilio-psoas haematomas (IPHs): a warning for COVID-19 inpatients

E. Nicastri, A. Antinori, P. Lorenzini, 2021, Annals of medicine.

Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia

C. Agrati, S. Topino, G. Ippolito, 2020, Scientific Reports.

Identification of HIV-1-specific regulatory T-cells using HLA class II tetramers

M. Altfeld, M. Addo, A. Antinori, 2012, AIDS.

Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, The Journal of antimicrobial chemotherapy.

Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.

M. Moroni, G. Filice, R. Maserati, 2008, AIDS patient care and STDs.

Drug plasma trough concentrations during treatment with daclatasvir and sofosbuvir are associated respectively with liver impairment and with renal dysfunction in HIV/HCV co-infected patients

C. Agrati, A. Antinori, R. Bellagamba, 2019 .

Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders

A. d’Arminio Monforte, A. Antinori, P. Cinque, 2012, AIDS research and treatment.

Liver Enzyme Elevation During Darunavir-Based Antiretroviral Treatment in HIV-1–Infected Patients With or Without Hepatitis C Coinfection: Data from the ICONA Foundation Cohort

A. d’Arminio Monforte, A. Antinori, P. Lorenzini, 2014, HIV clinical trials.

Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Reduced value of thallium-201 single-photon emission computed tomography in the management of HIV-related focal brain lesions in the era of highly active antiretroviral therapy.

A. Antinori, P. Lorenzini, L. Mango, 2004, AIDS research and human retroviruses.

Naïve/Effector CD4 T cell ratio as a useful predictive marker of immune reconstitution in late presenter HIV patients: A multicenter study

C. Agrati, F. Perna, A. Sacchi, 2019, PloS one.

Safety and efficacy of regimens containing emtricitabine in HIV-infected patients taking highly active antiretroviral therapy.

A. Antinori, P. Lorenzini, G. Liuzzi, 2006, The new microbiologica.

Virological response to Salvage Therapy in HIV-Infected Persons Carrying the Reverse Transcriptase K65R Mutation

F. Ceccherini‐Silberstein, A. Antinori, P. Lorenzini, 2007, Antiviral therapy.

Clinical and genotypic correlates of mutation K65R in HIV‐infected patients failing regimens not including tenofovir

F. Ceccherini‐Silberstein, P. Narciso, A. Antinori, 2006, Journal of medical virology.

Two Different Patterns of Mutations are Involved in the Genotypic Resistance Score for Atazanavir Boosted Versus Unboosted by Ritonavir in Multiple Failing Patients

F. Ceccherini‐Silberstein, R. Maserati, P. Narciso, 2009, Infection.

Switching to Coformulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients: Data From a Multicenter Cohort.

A. Antinori, R. Bellagamba, P. Lorenzini, 2015, Journal of acquired immune deficiency syndromes.

Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort

A. Antinori, R. Bellagamba, P. Lorenzini, 2014, Journal of the International AIDS Society.

The impact of DAA‐mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, A. Antinori, 2021, Journal of viral hepatitis.

Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort.

A. d’Arminio Monforte, P. Lorenzini, N. Abrescia, 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy.

A. d’Arminio Monforte, A. Antinori, P. Cinque, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Role of testosterone in SARS-CoV-2 infection: A key pathogenic factor and a biomarker for severe pneumonia

G. Ippolito, E. Nicastri, A. Antinori, 2021, International Journal of Infectious Diseases.

Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection

C. Agrati, M. Capobianchi, A. Antinori, 2022, Pharmaceuticals.

Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2018, The Journal of antimicrobial chemotherapy.

Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, BMC Public Health.

Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients

P. Narciso, A. Antinori, V. Tozzi, 2005, AIDS.

Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

Karin J. Metzner, Huldrych F. Günthard, E. Nicastri, 2014, The Journal of antimicrobial chemotherapy.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation

A. d’Arminio Monforte, A. Antinori, P. Lorenzini, 2017, AIDS Patients Care and STDs.

Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV

A. d’Arminio Monforte, A. Antinori, P. Lorenzini, 2017, Journal of acquired immune deficiency syndromes.

Role of serum free light chains in predicting HIV‐associated non‐Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy

A. d’Arminio Monforte, A. di Caro, A. Antinori, 2012, American journal of hematology.

Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)

A. d’Arminio Monforte, C. Agrati, E. Nicastri, 2023, eClinicalMedicine.

Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals

M. Capobianchi, A. Antinori, P. Lorenzini, 2017, PloS one.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital

C. Agrati, S. Topino, G. Ippolito, 2021, International Journal of Infectious Diseases.

The Effect of Number of Mutations and of Drug-Class Sparing on Virological Response to Salvage Genotype-Guided Antiretroviral Therapy

P. Narciso, A. Antinori, V. Tozzi, 2002, Antiviral therapy.

Real world efficacy of dolutegravir plus lamivudine in PLWH with undetectable viral load after previous failures.

A. Antinori, P. Lorenzini, C. Mussini, 2022, Journal of global antimicrobial resistance.

No significant association between patient self-reported non-adherence to antiretrovirals and HIV-tropism: a preliminary analysis

M. Capobianchi, P. Lorenzini, C. Perno, 2012, Journal of the International AIDS Society.

Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV

C. Agrati, E. Cimini, C. Castilletti, 2022, Nature Communications.

Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy

A. d’Arminio Monforte, P. Lorenzini, C. Mussini, 2018, BMC Public Health.

Declining Prevalence of Human Immunodeficiency Virus (HIV)–Associated Neurocognitive Disorders in Recent Years and Associated Factors in a Large Cohort of Antiretroviral Therapy–Treated Individuals With HIV

A. Antinori, R. Bellagamba, P. Lorenzini, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count

C. Agrati, E. Cimini, C. Castilletti, 2022, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

SARS-CoV-2 Specific Immune Response and Inflammatory Profile in Advanced HIV-Infected Persons during a COVID-19 Outbreak

C. Agrati, E. Cimini, C. Castilletti, 2022, Viruses.

Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2018, BMC Medicine.

Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA)

A. Antinori, P. Cinque, P. Lorenzini, 2011, Journal of NeuroVirology.

Characteristics and Outcomes of COVID-19-Related Hospitalization among PLWH

C. Agrati, E. Nicastri, A. Antinori, 2022, Journal of Clinical Medicine.

Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons

C. Agrati, A. Antinori, R. Bellagamba, 2021, European Journal of Drug Metabolism and Pharmacokinetics.

Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons

C. Agrati, A. Antinori, R. Bellagamba, 2021, European journal of drug metabolism and pharmacokinetics.

Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication

A. Antinori, P. Lorenzini, E. Girardi, 2014, Journal of the International AIDS Society.

Central nervous system penetration-effectiveness rank does not reliably predict neurocognitive impairment in HIV-infected individuals

E. Nicastri, A. Antinori, P. Balestra, 2014, Journal of the International AIDS Society.

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis

G. d’Ettorre, A. Giannetti, A. Antinori, 2014, Journal of the International AIDS Society.

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study

G. d’Ettorre, A. Giannetti, A. Antinori, 2016, BMC Infectious Diseases.

Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART.

A. d’Arminio Monforte, A. Antinori, P. Lorenzini, 2016, The Journal of antimicrobial chemotherapy.

The V118I Mutation as a Marker of Advanced HIV Infection and Disease Progression

F. Ceccherini‐Silberstein, P. Narciso, A. Antinori, 2007, Antiviral therapy.

Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, A. Antinori, 2020, Viruses.

Drug-Class-Wide Resistance to Antiretrovirals in HIV-Infected Patients Failing Therapy: Prevalence, Risk Factors and Virological Outcome

P. Narciso, A. Antinori, V. Tozzi, 2005, Antiviral therapy.

Vitamin D deficiency is associated with neurocognitive impairment in HIV-infected subjects

A. Antinori, P. Lorenzini, A. Ammassari, 2019, Infection.

A. Antinori, R. Bellagamba, P. Lorenzini, 2022, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

Liver stiffness reduction and serum fibrosis score improvement in HIV/hepatitis C virus‐coinfected patients treated with direct‐acting antivirals

A. Antinori, R. Bellagamba, P. Lorenzini, 2018, HIV medicine.

Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against SARS-CoV-2 in People Living with HIV (PLWH) Receiving Antiretroviral Therapy (ART) According with Current CD4 T-Lymphocyte Count

C. Agrati, E. Cimini, C. Castilletti, 2021, SSRN Electronic Journal.

The dual-target approach in viral HIV-1 viremia testing: An added value to virological monitoring?

M. Capobianchi, A. Antinori, P. Lorenzini, 2020, PloS one.

What is the impact of post-COVID-19 syndrome on health-related quality of life and associated factors: a cross-sectional analysis

A. Antinori, P. Lorenzini, E. Girardi, 2023, Health and Quality of Life Outcomes.

Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss

A. d’Arminio Monforte, A. Mammone, A. Antinori, 2021, Scientific Reports.

Neuroactive Antiretroviral Drugs Do Not Influence Neurocognitive Performance in Less Advanced HIV-Infected Patients Responding to Highly Active Antiretroviral Therapy

P. Narciso, A. Corpolongo, A. Antinori, 2006, Journal of acquired immune deficiency syndromes.

Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort

A. d’Arminio Monforte, P. Lorenzini, N. Abrescia, 2014, Journal of the International AIDS Society.

Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: Results from an urban observational cohort

P. Narciso, G. Ippolito, A. Corpolongo, 2005, Journal of NeuroVirology.

Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort*

A. d’Arminio Monforte, A. Antinori, P. Lorenzini, 2018, HIV clinical trials.

Historical resistance profile helps to predict salvage failure

Francesca Ceccherini-Silberstein, F. Ceccherini‐Silberstein, P. Narciso, 2009, Antiviral therapy.

Prevalence and Associated Factors of Neurocognitive Impairment in HIV-Positive Patients on Effective Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Treatment.

P. Narciso, E. Nicastri, A. Antinori, 2018, AIDS research and human retroviruses.

First‐line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, A. Lazzarin, 2018, HIV medicine.

Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunode ﬁ ciency virus * Clinical Microbiology and Infection

A. Antinori, P. Lorenzini, E. Girardi, 2017 .

C. Agrati, E. Cimini, C. Castilletti, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Historical resistance profile helps to predict salvage failure

F. Ceccherini‐Silberstein, P. Narciso, A. Antinori, 2009, Antiviral therapy.

Effect of Suppressing HIV Viremia on the HIV Progression of Patients Undergoing a Genotype Resistance Test after Treatment Failure

F. Ceccherini‐Silberstein, P. Narciso, V. Tozzi, 2009, Infection.

Progressive multifocal leukoencephalopathy in HIV-infected patients in the era of HAART: radiological features at diagnosis and follow-up and correlation with clinical variables.

A. Antinori, P. Lorenzini, C. Bibbolino, 2008, AIDS research and human retroviruses.

Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy.

A. d’Arminio Monforte, A. Antinori, P. Cinque, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.